PERITONEAL MEMBRANE CHARACTERISTICS IN SAUDI PATIENTS Prof. Jamal Alwakeel, Dr Saira Usama Dr Abdulkareem Alsuwaida, Dr Mohammad AL Ghonaim, Dr Akram.

Slides:



Advertisements
Similar presentations
Risk Stratification in Renal Care Mary Jane McKendry Vice President, Operations Fresenius Disease Management Optimal Renal Care.
Advertisements

Nuevas Soluciones en DP, Sirven? Prueba en diabéticos con transporte peritoneal alto y promedio alto Dr. José Ramón Paniagua Sierra Unidad de Investigación.
The Importance of Residual Renal Function Dr Paul Tam June 11, 2010.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
ESRD Registry Committee, Korean Society of Nephrology*
Renal Replacement Therapy: What the PCP Needs to Know.
Chronic Kidney Disease Treatment Options
Peritoneal Dialysis Adequacy & Prescription Management
Evaluation of HIV status and its spread in HIV patients on RRT and their spouses Dr. Aditya Agarwal Clinical Fellow Indraprastha Apollo Hospitals, New.
Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.
Chapter 12: USRDS Special Study Center on Transition of Care in CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
What is the Role of Peritoneal Dialysis in Optimising ESRD Patient Outcomes?
CAPD THE SAUDI EXPRIENCE THE SAUDI EXPRIENCE. Dialysis in Saudi Arabia There are 6700 patients on dialysis in Saudi Arabia There are 6700 patients on.
Anatomy and Physiology of Peritoneal Dialysis
Vol 2 Figure 1.1 Trends in the number of incident cases of ESRD, in thousands, by modality, in the U.S. population, Data Source: Reference.
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
Estimated GFR Based on Creatinine and Cystatin C
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
Rowan Walker – Chairman Chair: Steve Chadban ANZDATA update (Stephen McDonald) Analgaesic nephropathy – the end of an epidemic? (Sean Chang)
Outcome of patients started on PD as first line therapy, Saira Usama, Jamal S. Alwakeel, Ahmad H. Mitwalli, Abdulkareem Alsuwaida, Akram Askar, King Khalid.
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PERITONEAL DIALYSIS CHAPTER 6.
James Heaf Herlev Hospital University of Copenhagen
Renal Medicine David Johnson Princess Alexandra Hospital Brisbane, Australia A Comparison of APD vs CAPD on Patient Outcomes A Comparison of APD vs CAPD.
1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.
Why don’t indigenous dialysis patients receive transplants – waitlist or allocation? N. Khanal 1, P. Clayton 1, S. McDonald 1, M. Jose 2 1 The University.
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
Prescription of pediatric peritoneal dialysis
© ANZDATA Registry PEADIATRIC CHAPTER CHAPTER 11.
1 Adult Hemodialysis Longitudinal Follow-Up Data 2002–2008.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PAEDIATRIC CHAPTER 11.
ANZDATA Registry Overview Dr Graeme Russ Darwin September 2001 September 2001.
Chapter 10 Cancer 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Cancer Working.
Chapter 5 Peritoneal Dialysis 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Peritoneal.
“Adequacy in PD prescription What, How, When?
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.
Selected aspects of acid base physiology- acidosis in CKD
Kitty Jager & Anneke Kramer, Jane Tizard, Enrico Verrina, Vianda Stel and Karlijn van Stralen On behalf of he ERA-EDTA and ESPN Registry Committees ERA-EDTA.
© ANZDATA Registry Stock and Flow of CAPD Patients Australia Number of Patients 1504 Patients * (Data to 30 Sept) Extrapolated.
Figures from Dialysis and kidney transplantation in Australia 1991–2010.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
Long Term Peritoneal Dialysis In Children – Frequent Complications Conclusions: Peritoneal Dialysis is the method of choice for pediatric patients, with.
Obesity in the end stage kidney disease population
ASSOCIATION OF SOCIO-ECONOMIC POSITION WITH TECHNIQUE FAILURE AND MORTALITY IN AUSTRALIAN NON-INDIGENOUS PERITONEAL DIALYSIS PATIENTS Dr Samuel Chan Nephrology.
Optimization of pre-ESRD care: The key to improved dialysis outcomes
The HEMO Study Hemodialysis (HEMO) Study Reference
Therapy Modality: Continuous Ambulatory Peritoneal Dialysis (CAPD)
The ADEMEX Trial Adequacy of PD in Mexico Reference
ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.
Independent Samples Test Independent Samples Test
UK Renal Registry 9th Annual Report 2006
The CANUSA Trial Reference
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani
UK Renal Registry 10th Annual Report 2007
CHAPTER 5 Paediatric Renal Replacement Therapy
Buffer transport in peritoneal dialysis
Annie-Claire Nadeau-Fredette
Use of icodextrin in high transport ultrafiltration failure
A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.
Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy  G. Viglino, L. Neri, S. Barbieri  Kidney.
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
Volume 55, Issue 6, Pages (June 1999)
Benefits of preserving residual renal function in peritoneal dialysis
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Dialysis outcomes in Australia & New Zealand
ANZDATA Peritoneal Dialysis Report
Presentation transcript:

PERITONEAL MEMBRANE CHARACTERISTICS IN SAUDI PATIENTS Prof. Jamal Alwakeel, Dr Saira Usama Dr Abdulkareem Alsuwaida, Dr Mohammad AL Ghonaim, Dr Akram Askar, Dr Niaz Feraz, Dr Shahid Qayyum Dr Abdo Qudsi.

Global Prevalence of ESRD on RRT Lysaght, J Am Soc Nephrol, 2002 Saudi Center for Organ Transplantation, Annual Report

PD in KSA Saudi Center for Organ Transplantation, Annual Report

Important to understand To tailor the therapy To improve adequacy To improve technique survival Membrane Physiology and Transport Kinetics for the target population

Globally used Accurate and reliable over repeated periods of observation to determine membrane type Extremely well controlled In-center procedure Mujais S, Nolph K, Gokal R, et al: Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20:S5-S21, 2000 (suppl 4)

Low-average Low Transporter < 0.50 High- average High Transporters > 0.80

Baseline Peritoneal Equilibrium Test Gokal R, Mallick NP: Peritoneal dialysis. 1999

 To identify the characters of membrane permeability in the local Saudi population  assess the role of various factors affecting solute transport across the peritoneal membrane Aim of the Study

Patients and methods 52 patients in the Peritoneal Dialysis Unit of King Khalid University Hospital, Riyadh

Primary cause of ESRD

ST DEVMAXMINMEAN BMI BSA RESIDUAL RENAL FUNCTION (ML/DAY) Patient characteristics  The average age 50.5 yrs  24 patients were above 60 yrs of age

UREACRTCAPHOSPTHHB ALBU MIN Total Kt/V Total Cr Cl L/wk Hb Gm/dl EPO DOSE Mean Min Max ,000 Std dev Results

 The average daily glucose exposure was ( ± 58.63) gm per day.  31 patients were using icodextrin either as night cycle in CAPD or as Long day dwell in CCPD patients. PD Fluids

High transporter7 High Average19 Low Average13 Low Transporter1 RESULTS Membrane type in Saudi patients

DIABETIC PATIENTS

Older Age Group 46 % patients - above 60 yrs of age

COMPARING WITH OTHER POPULATIONS

 54 adult PD patients at Kingston General Hospital, Kingston, Ontario, Canada.  distribution of the patients by peritoneal transport 0 low 17 low-average 22 high-average 15 high 1.Rachel M. Pilkeyet al Inflammation, Peritoneal Transport, and Response to Erythropoitin in Peritoneal Dialysis Patients Queen’s University and Kingston General Hospital, Kingston, Ontario, Canada Perit Dial Int 31:48–63, 2006 Canada

 The study group at Department of Nephrology and Mineral Metabolism,, Mexico DF,  55 patients (29 male, 26 female) Peritoneal transport distribution:  24% - low  29% - low average  34% - high average  13% - high transporter Angel Diaz-Alvarenga, Marcela Abasta-Jimenez, Bemardo Bravo, Gerardo Gamba, Ricardo Correa-Rotter Serum Albumin and Body Surface Area Are the Strongest Predictors of the Peritoneal Transport Type Perit Dial Int 23:75–89, 2004 Mexico

 918 patients from the Australian and New Zealand Dialysis and Transplant registry  153 (16.7%) - H  472 (51.4%) - (HA),  257 (28.0%) - (LA)  36 (3.9%) - (L). 1.Rumpsfeld M, McDonald SP, Purdie DM, Collins J, Johnson DW: Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 43:492–501, 2004 ANZDATA

Comparatively Speaking

 The results are comparable to other populations  The slight differences could be explained by the pre existing renal disease, co morbidities as well as the racial differences  There is need for a national renal registry to fully understand the membrane kinetics in the local population CONCLUSION